Brought to you by 
Genetic analysis specialist Sequenom nets $92mm in public offer
08 Jul 2008
Executive Summary
Sequenom (platforms for genetic research and molecular diagnostics) netted $92mm through the follow-on public sale of 6.3mm shares (including the overallotment) at $15.50 each. The company will put the money towards developing noninvasive diagnostics that use its nucleic acid analysis system MassARRAY. Under a license from the Chinese University of Hong Kong, Sequenom is initially focusing on prenatal testing to identify fetal gene and chromosome abnormalities.
Deal Industry
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com